This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), ...

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis.

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

Johnson & Johnson announced that the Tremfya Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...